This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Healthcare Provider Remove Pharma Remove Pharmaceutical manufacturing Remove Prescription
article thumbnail

US legislative update: takeaways for European pharma

European Pharmaceutical Review

NOVEMBER 8, 2022

In the current US Congressional session, Congress has focused heavily on legislation directed at reducing prescription drug prices. The new law will also require drug manufacturers to pay rebates to Medicare if they increase drug prices faster than consumer inflation. Actavis, 570 U.S. 136 (2013), [link] opinions/12pdf/12-416_m5n0.pdf.

Food and Drug Administration 52
Food and Drug Administration Pharma Prescription Manufacturing 52
article thumbnail

Diversity and inclusion in oncology clinical trials

Clarify Health

OCTOBER 26, 2021

In this blog, we take a close look at health equity in oncology trials specifically, assessing how the lack of diversity and inclusion has impacted cancer patients and the pharma industry’s key initiatives to address it. Clarify launched its real-world evidence on health disparities in 2021.

Food and Drug Administration 52
Food and Drug Administration Recruitment Pharmaceutical manufacturing Medical 52
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 8,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024